Propanc Biopharma, Inc. Common Stock (PPCB) - Total Assets
Based on the latest financial reports, Propanc Biopharma, Inc. Common Stock (PPCB) holds total assets worth $14.33 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Propanc Biopharma, Inc. Common Stock - Total Assets Trend (2010–2025)
This chart illustrates how Propanc Biopharma, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. Also see PPCB company net worth for the company's overall valuation and market capitalisation.
Propanc Biopharma, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (June 2025)
Propanc Biopharma, Inc. Common Stock's total assets of $14.33 Million consist of 42.6% current assets and 57.5% non-current assets. Review Propanc Biopharma, Inc. Common Stock debt and liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.1% |
| Accounts Receivable | $5.30K | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2010–2025)
This chart illustrates how Propanc Biopharma, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest Propanc Biopharma, Inc. Common Stock stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Propanc Biopharma, Inc. Common Stock's current assets represent 42.6% of total assets in 2025, a decrease from 91.1% in 2010.
- Cash Position: Cash and equivalents constituted 0.1% of total assets in 2025, down from 1.2% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2010.
- Asset Diversification: The largest asset category is accounts receivable at 0.0% of total assets.
Propanc Biopharma, Inc. Common Stock Competitors by Total Assets
Key competitors of Propanc Biopharma, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Vaxcyte Inc
NASDAQ:PCVX
|
USA | $3.14 Billion |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $1.11 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.16 Billion |
Propanc Biopharma, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.37 | 2.24 | 0.00 |
| Quick Ratio | 2.37 | 2.24 | 0.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $4.75 Million | $5.39 Million | $-3.07 Million |
Propanc Biopharma, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Propanc Biopharma, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.28 |
| Latest Market Cap to Assets Ratio | 0.10 |
| Asset Growth Rate (YoY) | 27028.9% |
| Total Assets | $19.63 Million |
| Market Capitalization | $1.94 Million USD |
Valuation Analysis
Below Book Valuation: The market values Propanc Biopharma, Inc. Common Stock's assets below their book value (0.10x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Propanc Biopharma, Inc. Common Stock's assets grew by 27028.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Propanc Biopharma, Inc. Common Stock (2010–2025)
The table below shows the annual total assets of Propanc Biopharma, Inc. Common Stock from 2010 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $19.63 Million | +27028.87% |
| 2024-06-30 | $72.36K | +19.95% |
| 2023-06-30 | $60.33K | -26.11% |
| 2022-06-30 | $81.65K | +523.24% |
| 2021-06-30 | $13.10K | -86.70% |
| 2020-06-30 | $98.52K | -3.08% |
| 2019-06-30 | $101.65K | +42.40% |
| 2018-06-30 | $71.39K | -24.91% |
| 2017-06-30 | $95.07K | -74.93% |
| 2016-06-30 | $379.14K | -39.54% |
| 2015-06-30 | $627.07K | +451.29% |
| 2014-06-30 | $113.75K | +6410.88% |
| 2013-06-30 | $1.75K | -96.22% |
| 2012-06-30 | $46.27K | -99.57% |
| 2011-06-30 | $10.81 Million | +24554.96% |
| 2010-06-30 | $43.86K | -- |
About Propanc Biopharma, Inc. Common Stock
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. Th… Read more